A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

See ANZCTR for full trial details >

 

Trial Summary:

To establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal NECs. To explore translational biologic, molecular and functional imaging endpoints to inform future research and improve outcomes for NEC patients.

Supported By:

Specialised Therapeutics Australia (STA), AGITG and the NHMRC.

Eligibility:

Adults with histologically confirmed advanced and/or metastatic, WHO ENET Grade 3, unresectable gastrointestinal NECs, including both small cell and large cell-NEC.

Registration ID:

ACTRN12616000958482

Participation:

Australia

Australian Lead Group:

AGITG

Status:

Open

Activation Date:

15/09/2016

Chairs:

Dr Lorraine Chantrill

Contact:

nabnec.study@sydney.edu.au